newsfilter
← Latest News
Business Wire·

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026

  • Omeros Corporation will report third-quarter 2026 financial results after market close on Monday, November 16, 2026.
  • Management will host a conference call & webcast at 4:30 p.m. Eastern Time to discuss results & company developments.
  • The live webcast is accessible via a provided link or the "Upcoming Events" section of the Investor Relations page.
  • A replay of the call will remain available for 90 days in the "Archived Events" section.
  • Users should allow extra login time as the company transitions to a new platform hosted by Q4 Inc.
  • Omeros focuses on protein & small-molecule therapeutics for complement-mediated diseases, cancers, & addictive disorders.
  • The FDA-approved lead product YARTEMLEA treats TA-TMA in adult & pediatric patients aged two years & older.
  • Long-acting MASP-2 inhibitor OMS1029 has completed Phase 1 clinical trials.
  • Novo Nordisk holds global rights to zaltenibart, an MASP-3 inhibitor in development for PNH & other indications.
  • Omeros pipeline includes OMS527, a PDE7 inhibitor for cocaine use disorder funded by the National Institute on Drug Abuse.
  • The company also develops recombinant antibodies for multidrug-resistant organisms & novel oncology therapeutic programs.